All In Biotech

Drug Trial Radar · NCT07731802

Finasteride and Cutibacterium

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Mar 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

High levels of Testosterone causes high amounts of skin bacteria (Cutibacterium Acnes) which can go into the skin during a shoulder replacement surgery and cause a terrible infection. The goal of this experiment is to have participants take Finasteride, a medication that blocks testosterone production, for 2 weeks and evaluate the following: * Blood levels of testosterone * Amount of bacteria on the skin. Participants will: * Be assigned to take Finasteride, or a placebo (a look-alike pill with no active medicine) once daily, for 2 weeks * Have a small sample of their blood collected and their skin swabbed with a Q-tip to determine Testosterone levels and bacteria on the skin * Blood draw and skin testing will take place before starting Finasteride or the placebo (day 0) and at the end of the experiment (day 14).

Conditions

  • Dihydrotestosterone
  • Periprosthetic Joint Infection (PJI)
  • Cutibacterium Acnes

Interventions

  • Finasteride 5 mgDrug

    Patients randomized to the experimental group will receive oral Finasteride 1 mg, taken daily, for two weeks

  • Placebo ControlDrug

    Patients randomized to the placebo group will receive one pill containing no active medicine, taken daily, for two weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cutibacterium skin loadTime frame: Skin load will be assessed at day 0 and at the end of the study on day 14 of treatment or placebo.
  2. Serum Dihydrotestosterone (DHT) LevelTime frame: levels will be assessed at baseline and after 14 consecutive days of treatment or placebo.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UW Medical Center - Montlake

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.